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Viruses are a widespread persistent threat to human health, and for the most dangerous threats,
effective antiviral therapies or vaccines are often still lacking. To combat the rapid pace of viral
evolution and the continual emergence of new strains, broadly neutralizing therapies or vaccines
that can target multiple strains are in high demand. In this Select, we look at recent papers that
are helping to advance antiviral research on several fronts.‘‘Enveloped’’ (left) and nonenveloped (right) hepa-
titis A virus particles released from infected
hepatoma cell cultures. Image courtesy of The
University of North Carolina at Chapel Hill.Viral Masquerade
Any student of virology knows there are two categories of viruses: those that
are surrounded by a lipid bilayer that is needed for cellular entry and infec-
tivity (enveloped), and those that are not (nonenveloped). In an interesting
twist on this long-established dichotomy, Feng et al. (2013) show that the
human pathogen hepatitis A virus, a nonenveloped picornavirus, is cloaked
in a membrane of host lipids when released from cells, allowing it to
masquerade as an enveloped virus and limiting its exposure to the immune
system. Although no more infectious than nonenveloped HAV, these virus-
containing, exosome-like particles (termed eHAV) are unrecognized by com-
mon antibodies against hepatitis A virus, possibly facilitating viral spread
in vivo. Furthermore, knockdown of the energy-generating ATPase VPS4B
or the exosome biogenesis protein Alix prevents the release of eHAV as
well as the production of naked virus, suggesting that this formerly unrecog-
nized particle may be an intermediate in the life cycle of hepatitis A. Impor-
tantly, enveloped eHAV particles are the form of virus that circulates in theblood in humans with acute hepatitis A. In yet another distinction between enveloped and nonenveloped hepatitis A, the
entry of eHAV into cells relies on successful acidification of endosomes, which is effectively blocked by treatment with chlo-
roquine. Vaccination against hepatitis A is a very successful strategy for limiting infection, and given that viral particles are not
accessible to antibody recognition when circulating as eHAV, it appears that the mechanisms by which HAV is neutralized
in vivo are more complicated than previously thought. How many other viruses take advantage of this stealth tactic in vivo
and whether these pathways of viral escape can be targeted therapeutically are just two more of the many important and
fascinating questions raised by the observations described in this report.
Feng, Z. (2013). Nature. Published online March 31, 2013. http://dx.doi.org/10.1038/nature12029.Highly heterogeneous proteins like
ABCE1 may be part of ‘‘next generation’’
drug targets, provided the implicated
subset can be distinguished, as done
by Lingappa et al. for rabies capsid
assembly (red box). Image courtesy of
U.F. Lingappa.Targeting the Host-Virus Machinery
Infection with rabies virus is nearly always deadly to humans if postexposure vacci-
nation cannot be started within a narrow time frame, and small-molecule treatments
are entirely lacking for this disease. In an interesting, unbiased approach to drug
discovery, Lingappa et al. (2013) target the viral and host proteins that produce
virus capsid, the protein structure that encases viral nucleic acid. Although capsid
formation is often viewed as a process of spontaneous self-assembly, the authors
follow up on data suggesting that host factors are crucial for catalyzing the
processes that generate functional capsid and create a screening method that
does not rely on prior knowledge of the factors involved. Using cell-free protein
synthesis to generate capsids in vitro, they design a plate-based fluorescent screen
to identify small molecules that disrupt capsid production at some point on the
pathway from protein synthesis to capsid assembly. Several compounds with
robust antiviral activity in cell culture and promising pharmacodynamic properties
are identified from this approach. Using one of the most selective compounds,
they go on to isolate host-derived machinery components including ATP-binding
cassette family protein E1 (ABCE1), which has been implicated in capsid assembly for HIV. In addition to the potential
this screening strategy may have for targeting complex protein mixtures without the need for laborious purification, this
work highlights new pathways of investigation into virus-host interactions and expands the universe of potential targets
for further drug discovery.
Lingappa, U., et al. (2013). Proc. Natl. Acad. Sci. USA 110, E861–E868.Cell 153, May 9, 2013 ª2013 Elsevier Inc. 727
A cryoelectron microscopy reconstruc-
tion of the high-temperature dengue vi-
rus ‘‘bumpy’’ surface, colored according
to the radial distance of the surface
from the viral center. Image courtesy of
M. Rossmann.Visualizing the Target
A key aspect of successful antibody targeting is the exposure of any given epitope
for binding an antibody, and one recent article provides a new view of the surface
architecture of dengue virus obtained using cryoelectron microscopy. Transmitted
to humans via mosquito bites, dengue virus usually causes no symptoms or a rela-
tively mild disease known as dengue fever, which is endemic in many countries
worldwide. However, a small fraction of cases progress to the more dangerous dis-
eases dengue hemorrhagic fever or dengue shock syndrome. No effective vaccine
is currently available, and available therapies target the symptoms but not the virus
itself. The structure of the mature dengue virus is known, and it has a smooth viral
surface, unless induced to change structure by a reduction in pH. In contrast to the
smooth surface observed previously, Zhang et al. (2013) describe a novel ‘‘bumpy’’
viral structure after incubation at temperatures greater than approximately 33C,
i.e., at temperatures similar to those of human hosts. An apparently irreversible struc-
tural transition occurs between 31C and 35C, a transition that corresponds with a
modest increase in infectivity. Zhang et al. propose that the ‘‘bumpy’’ structure is
the predominant form of the virus in humans and represents an intermediate capable
of fusing with cells. This suggests that future vaccine design should take into account
the arrangement of surface proteins observed at higher temperatures and may pave
the way for more substantial progress in developing an effective vaccine.Zhang, X., et al. (2013). Proc. Natl. Acad. Sci. USA. Published online April 8, 2013. http://dx.doi.org/10.1073/pnas.
1304300110.A cartoon of a viral fitness landscape in-
ferred by the approach of Ferguson et al.;
Image courtesy of A. Chakraborty.Designer Antibodies and T Cells
For HIV, the rapid rate of viral mutation and immune escape is one of the biggest chal-
lenges to successful vaccine development. Two recent papers present two methods
to help understand the effects of mutations on interactions between the immune sys-
tem and viral particles. In a report that sheds light on the coevolution of viruses and
antibodies, Liao et al. (2013) sequence a series of viruses and antibodies isolated
from a single host over an extended time period. By following the mutational progres-
sion of both the viral envelope (ENV) protein and the host antibodies, the authors find
that recognition of the founder virus by the ancestor antibody appears to drive viral
epitope diversification and selection, which is then followed by the evolution of a
broadly neutralizing antibody, suggesting an ordered sequence of coevolution.
They also find that the pathway by which broadly neutralizing antibodies develop is
surprisingly less complex than has been previously shown and identify viral protein
sequences (both initial and mutated) that might form the basis of an effective vacci-
nation strategy. In a second report, Ferguson et al. (2013) present a computational
approach to infer quantitative HIV viral fitness landscapes from sequence databases. This allows the identification of regions
for which mutations (single andmultiple) impart a high fitness cost, thus they are attractive as immunogens for vaccine devel-
opment. Although developed in the context of HIV, similar models may be helpful for vaccine design in the context of other
rapidly mutating viruses or even in the design of vaccines against cancer. Both reports provide significant insight into the
sequences most likely to produce robust, effective immune responses after vaccination for HIV.
Liao, H.-X., et al. (2013). Nature. Published online April 3, 2013. http://dx.doi.org/10.1038/nature12053.
Ferguson, A. L., et al. (2013). Immunity 38, 606–617.
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